Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Wearable HRV Biofeedback for Stress in Dementia Caregivers (CARE-COHERENCE)

5 de novembro de 2026 atualizado por: Instituto de Investigación Marqués de Valdecilla

Low-cost Wearable Heart Rate Variability Biofeedback as a Nurse-led Intervention to Reduce Stress in Informal Caregivers of People With Dementia: a Prospective Controlled Non-randomized Interventional Trial

This study will evaluate whether a nurse-led heart rate variability (HRV) biofeedback programme supported by a low-cost wearable sensor reduces autonomic dysregulation and perceived stress in informal caregivers of people with dementia. Participants will be prospectively allocated, without randomization, at the day-care-centre level. Before enrolment, the six centres will be characterised according to centre size, estimated number of eligible caregivers and expected recruitment volume, and arranged into three approximately matched pairs. One centre in each pair will implement CARE-COHERENCE and the other will serve as a concurrent comparison centre under a pre-specified operational implementation plan. Follow-up will continue for 12 months.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Approximately 100 informal caregivers of older people with dementia attending one of six participating day-care centres will be enrolled. The intervention group will receive an 8-week HRV-biofeedback programme in addition to usual caregiver support. The comparison group will receive usual caregiver support during the 12-month study period and will be offered access to programme materials after completion of the final assessment. The primary outcome is change in resting root mean square of successive differences (RMSSD) from baseline to 6 months. Perceived stress is the key secondary outcome. Assessments occur at baseline, 8 weeks, 6 months and 12 months.

Tipo de estudo

Intervencional

Inscrição (Estimado)

100

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Cantabria
      • Santander, Cantabria, Espanha
        • Recrutamento
        • Hospital Universitario Marqués de Valdecilla
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adult (18 years or older) self-identified informal, unpaid caregiver of an older person with a clinical diagnosis of dementia attending one of the participating day-care centers.
  • Providing an average of at least 28 hours of unpaid care per week for a minimum of 3 months.
  • Able to understand study procedures and provide written informed consent.
  • Able to use a smartphone and a simple wearable device, independently or with brief study support.

Exclusion Criteria:

  • Persistent or clinically significant cardiac arrhythmia preventing reliable interbeat-interval analysis.
  • Pacemaker-dependent rhythm or another condition that, in the investigator's judgment, precludes valid heart rate variability assessment.
  • Current participation in formal heart rate variability biofeedback or structured resonance-frequency breathing training, or equivalent training within the previous 3 months.
  • Severe uncontrolled psychiatric illness or cognitive impairment precluding informed consent or meaningful participation.
  • Concurrent enrollment in another structured stress-reduction intervention trial.
  • Note: use of heart rate-modifying medication, including beta-blockers, is not an exclusion criterion. Medication use is documented prospectively and considered in prespecified sensitivity analyses.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: CARE-COHERENCE HRV biofeedback program

Participants receive an 8-week nurse-led heart rate variability (HRV) biofeedback program in addition to usual caregiver support. At program entry, an individual resonance frequency is determined using paced-breathing trials across a prespecified range of approximately 4.5 to 6.5 breaths per minute. The active phase comprises four weekly nurse-led sessions of approximately 60 minutes during weeks 1-4, followed by structured supported home practice during weeks 5-8. Sessions cover the physiological rationale for HRV biofeedback, paced breathing at the selected training frequency, interpretation of simple wearable feedback, management of common practice difficulties, and a brief positive-emotion self-regulation strategy. Participants are encouraged to practice approximately 10 minutes twice daily, or to reach a minimum accumulated practice target of 70 minutes per week. One booster contact occurs at month 3.

Nurse-delivered behavioral self-regulation training combining individualized resonance-frequency paced breathing with real-time HRV feedback from a low-cost wrist- or chest-worn sensor capable of recording interbeat intervals, paired with a compatible training application. Dose: four supervised sessions of approximately 60 minutes in weeks 1-4, delivered individually or in small groups, followed by supported home practice in weeks 5-8 (target 10 minutes twice daily, or at least 70 accumulated minutes per week), plus one booster contact at month 3. Training frequency is set per participant during an initial paced-breathing assessment across approximately 4.5-6.5 breaths per minute. A brief positive-emotion self-regulation strategy is included. The device model, firmware, and application version are prespecified before recruitment and held constant where possible. Adherence is derived from device and application logs and a participant practice log.

Outros nomes:
  • Treino de respiração em frequência de ressonância
  • CARE-COHERENCE program
Sem intervenção: Usual caregiver support

Participants continue to receive usual caregiver support, including routine clinical care, information, and standard services available through the participating day-care centers and other routine health and social care services. They do not receive structured resonance-frequency breathing training or HRV biofeedback from the study team at any point during the 12-month study period. After the 12-month assessment, participants in this group will be offered access to the CARE-COHERENCE educational materials and a program orientation session.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in resting RMSSD
Prazo: Baseline and 6 months

Root mean square of successive differences (RMSSD) derived from a standardised resting interbeat-interval recording obtained with the study wearable sensor and processed according to a prespecified HRV analysis protocol. Higher values indicate greater vagally mediated heart rate variability.

Baseline and 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in perceived stress (Perceived Stress Scale, PSS-10)
Prazo: Baseline, 8 weeks, 6 months and 12 months

Perceived stress measured with the 10-item Perceived Stress Scale (PSS-10). Total score ranges from 0 to 40. Higher scores indicate greater perceived stress; a decrease indicates improvement. Analyzed as change from baseline and as the follow-up value adjusted for the baseline score. This is the key secondary outcome.

Baseline, 8 weeks, 6 months and 12 months
Maintenance of resting RMSSD at 12 months
Prazo: Baseline and 12 months

Root mean square of successive differences (RMSSD, in milliseconds) derived from a standardized resting interbeat-interval recording obtained with the study wearable sensor and processed with the prespecified HRV analysis pipeline. Higher values indicate greater vagally mediated heart rate variability. Assesses whether any intervention effect on the primary outcome is maintained six months after the primary endpoint.

Baseline and 12 months
Change in caregiver burden (Zarit Burden Interview, ZBI-22)
Prazo: Baseline, 8 weeks, 6 months and 12 months

Caregiver burden measured with the 22-item Zarit Burden Interview. Total score ranges from 0 to 88. Higher scores indicate greater burden; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in resting SDNN
Prazo: Baseline, 8 weeks, 6 months and 12 months

Standard deviation of normal-to-normal interbeat intervals (SDNN, in milliseconds) from the same standardized resting recording used for the primary outcome. Higher values indicate greater overall heart rate variability.

Baseline, 8 weeks, 6 months and 12 months
Change in mean resting heart rate
Prazo: Baseline, 8 weeks, 6 months and 12 months

Mean heart rate in beats per minute derived from the standardized resting interbeat-interval recording.

Baseline, 8 weeks, 6 months and 12 months
Change in well-being (WHO-5 Well-Being Index)
Prazo: Baseline, 8 weeks, 6 months and 12 months

Well-being measured with the five-item WHO-5 Well-Being Index. The raw score ranges from 0 to 25 and is multiplied by 4 to give a percentage score from 0 to 100. Higher scores indicate better well-being; an increase indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, HADS)
Prazo: Baseline, 8 weeks, 6 months and 12 months

Symptoms measured with the Hospital Anxiety and Depression Scale. The HADS-Anxiety and HADS-Depression subscales are reported separately; each ranges from 0 to 21. Higher scores indicate more severe symptoms; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Carmen Sarabia Cobo, University of Cantabria

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de outubro de 2026

Conclusão Primária (Estimado)

30 de abril de 2028

Conclusão do estudo (Estimado)

31 de outubro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de novembro de 2026

Primeira postagem (Real)

12 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CARE-COHERENCE

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data underlying the results reported in the primary publication, together with the data dictionary, may be made available to qualified researchers whose proposed use has been approved by the study team. Data will be shared subject to a data-sharing agreement, applicable ethics committee requirements, and EU General Data Protection Regulation and Spanish data-protection law. Requests should be addressed to the corresponding author.

Prazo de Compartilhamento de IPD

Beginning 6 months after publication of the primary results report, with no specified end date.

Critérios de acesso de compartilhamento IPD

Requests from qualified researchers with a methodologically sound proposal, reviewed by the study team, and subject to a signed data-sharing agreement and to applicable ethics and EU/Spanish data-protection requirements. Requests should be sent to the corresponding author.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .